Trends in Recommendations for Myelosuppressive Chemotherapy for the Treatment of Solid Tumors

View More View Less
  • 1 From South Carolina Oncology Associates, Columbia, South Carolina.

Lung, breast, and colorectal cancers are the 3 most frequent causes of cancer-related death in the United States. In the past 15 years, survival has increased dramatically for patients with these tumor types, partly because improved chemotherapy caused major changes in standard care. In addition, maintaining chemotherapy dose intensity has an established a positive effect on patient outcomes. However, delivering chemotherapy at full dose and on schedule is limited primarily by myelosuppression. To determine how expert opinion about preferred chemotherapy for lung, breast, and colorectal cancers has changed over the past decade, the National Comprehensive Cancer Network (NCCN) treatment guidelines from 1996, 2000 or 2001, and 2005 for each tumor type were compared. The myelosuppressive potentials of NCCN-recommended agents were assessed using data from their prescribing information. Many agents and combinations of agents recommended in the NCCN guidelines for treating lung, breast, and colorectal cancers are associated with myelosuppression. Several of these myelosuppressive regimens, which were previously recommended for treating advanced-stage or metastatic disease, are now preferred for early-stage disease, and neoadjuvant or adjuvant therapy is now recommended in more tumor types and stages than ever before. These findings indicate that the cytotoxic agents and regimens recommended today are associated with more myelosuppression than those preferred a decade ago and are more widely used in early-stage disease when survival benefits are possible. Because of this trend toward more intensive treatment of patients with cancer, proactive steps should be taken to minimize the risk for myelosuppression and its complications while optimizing the relative dose intensity.

If the inline PDF is not rendering correctly, you can download the PDF file here.

Correspondence: Robert Smith, Jr., MD, South Carolina Oncology Associates, 166 Stoneridge Drive, Columbia, SC 29210. E-mail: rsmith@sconcology.net
  • 1.

    Jemal A, Murray T, Ward E. Cancer statistics, 2005. CA Cancer J Clin 2005;55:1030.

  • 2.

    American Cancer Society. Cancer Facts and Figures 2005. Atlanta, GA: American Cancer Society; 2005.

  • 3.

    Ettinger DS, Argiris A, Bepler G. The NCCN Non-Small Cell Lung Cancer Clinical Practice Guidelines, version 2, 2006. Available at: http://www.nccn.org. Accessed May 23, 2006.

    • Search Google Scholar
    • Export Citation
  • 4.

    Kim ES, Vokes EE, Kies MS. Cetuximab in cancers of the lung and head & neck. Semin Oncol 2004;31(suppl 1):6167.

  • 5.

    Hryniuk W, Levine MN. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 1986;4:11621170.

    • Search Google Scholar
    • Export Citation
  • 6.

    Bonadonna G, Valagussa P, Moliterni A. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995;332:901906.

    • Search Google Scholar
    • Export Citation
  • 7.

    Budman DR, Berry DA, Cirrincione CT. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 1998;90:12051211.

    • Search Google Scholar
    • Export Citation
  • 8.

    Mayers C, Panzarella T, Tannock IF. Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma. Cancer 2001;91:22462257.

    • Search Google Scholar
    • Export Citation
  • 9.

    Hryniuk W, Frei E III, Wright FA. A single scale for comparing dose-intensity of all chemotherapy regimens in breast cancer: summation dose-intensity. J Clin Oncol 1998;16:31373147.

    • Search Google Scholar
    • Export Citation
  • 10.

    Jakobsen A, Berglund A, Glimelius B. Dose-effect relationship of bolus 5-fluorouracil in the treatment of advanced colorectal cancer. Acta Oncol 2002;41:525531.

    • Search Google Scholar
    • Export Citation
  • 11.

    Scheithauer W, Kornek GV, Raderer M. Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2003;21:13071312.

    • Search Google Scholar
    • Export Citation
  • 12.

    Johnson BE, Argiris A, Crawford J. The NCCN Small Cell Lung Cancer Clinical Practice Guidelines, version 1, 2006. Available at: http://www.nccn.org. Accessed May 23, 2006.

    • Search Google Scholar
    • Export Citation
  • 13.

    Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 2003;21:45244531.

    • Search Google Scholar
    • Export Citation
  • 14.

    Lyman GH, Dale DC, Friedberg J. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol 2004;22:43024311.

    • Search Google Scholar
    • Export Citation
  • 15.

    Cairo MS. Dose reductions and delays: limitations of myelosuppressive chemotherapy. Oncology 2000;14(suppl 8):2131.

  • 16.

    Chang J. Chemotherapy dose reduction and delay in clinical practice: evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer. Eur J Cancer 2000;36(suppl 1):S11S14.

    • Search Google Scholar
    • Export Citation
  • 17.

    Ozer H, Armitage JO, Bennett CL. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 2000;18:35583585.

    • Search Google Scholar
    • Export Citation
  • 18.

    Link BK, Budd GT, Scott S. Delivering adjuvant chemotherapy to women with early-stage breast carcinoma: current patterns of care. Cancer 2001;92:13541367.

    • Search Google Scholar
    • Export Citation
  • 19.

    Scagliotti GV, Novello S. Role of erythropoietin in the treatment of lung cancer associated anaemia. Lung Cancer 2001;34(suppl 4):S91S94.

    • Search Google Scholar
    • Export Citation
  • 20.

    Pirker R, Wiesenberger K, Pohl G, Minar W. Anemia in lung cancer: clinical impact and management. Clin Lung Cancer 2003;5:9097.

  • 21.

    National Cancer Institute. Cancer Therapy Evaluation Programs, Common Toxicity Criteria Manual. Version 2.0; June 1, 1999. Available at: http://ctep.cancer.gov/forms/CTCManual_v4_10-4-99.pdf. Accessed June 13, 2006.

    • Search Google Scholar
    • Export Citation
  • 22.

    Demetri G, Elias A, Gershenson D. NCCN Small-Cell Lung Cancer Practice Guidelines.™ The National Comprehensive Cancer Network. Oncology (Huntingt) 1996;10(11 suppl):179194.

    • Search Google Scholar
    • Export Citation
  • 23.

    Ettinger DS, Cox JD, Ginsberg RJ. NCCN Non-Small-Cell Lung Cancer Practice Guidelines.™ The National Comprehensive Cancer Network. Oncology (Huntingt) 1996;10(11 suppl):81111.

    • Search Google Scholar
    • Export Citation
  • 24.

    Ettinger DS, Kris MG. NCCN Non-Small Cell Lung Cancer Practice Guidelines™ Panel. NCCN: Non-small cell lung cancer. Cancer Control 2001;8(suppl 2):2231.

    • Search Google Scholar
    • Export Citation
  • 25.

    Johnson BE. NCCN Small Cell Lung Cancer Practice Guidelines Panel. NCCN: small cell lung cancer. Cancer Control 2001;8(6 suppl 2):3243.

    • Search Google Scholar
    • Export Citation
  • 26.

    Carlson RW, Goldstein LJ, Gradishar WJ. NCCN Breast Cancer Practice Guidelines.™ The National Comprehensive Cancer Network. Oncology (Huntingt) 1996;10(11 suppl):4775.

    • Search Google Scholar
    • Export Citation
  • 27.

    Carlson RW, Anderson BO, Bensinger W. NCCN Breast Cancer Clinical Practice Guidelines, version 1, 2005. Available at: http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf. Accessed May 23, 2006.

    • Search Google Scholar
    • Export Citation
  • 28.

    Carlson RW, Anderson BO, Bensinger W. NCCN Practice Guidelines for Breast Cancer. Oncology (Huntingt) 2000;14:3349.

  • 29.

    Engstrom PF, Benson AB III, Cohen A. NCCN Colorectal Cancer Practice Guidelines. The National Comprehensive Cancer Network. Oncology (Huntingt) 1996;10(11 suppl):140175.

    • Search Google Scholar
    • Export Citation
  • 30.

    Engstrom PF, Benson AB III, Chen Y-J. NCCN Colon Cancer Clinical Practice Guidelines, version 2, 2005. Available at: http://www.nccn.org/professionals/physician_gls/PDF/colon.pdf. Accessed May 23, 2006.

    • Search Google Scholar
    • Export Citation
  • 31.

    Engstrom PF, Benson AB III, Chen Y-J. NCCN Rectal Cancer Clinical Practice Guidelines, version 1, 2005. Available at: http://www.nccn.org/professionals/physician_gls/PDF/rectal.pdf. Accessed May 23, 2006.

    • Search Google Scholar
    • Export Citation
  • 32.

    Benson AB III, Choti MA, Cohen AM. NCCN Practice Guidelines for Colorectal Cancer. Oncology (Huntingt) 2000;14:203212.

  • 33.

    Alimta [package insert]. Indianapolis, IN; Eli Lilly & Co; 2004.

  • 34.

    Caelyx [package insert]. Bruxelles, Belgium; SP Europe; 2005.

  • 35.

    Taxol [package insert]. Princeton, NJ: Bristol-Meyers Squibb Co; 2003.

  • 36.

    Navelbine [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2003.

  • 37.

    Taxotere [package insert]. Bridgewater, NJ: Aventis Pharmaceuticals; 2004.

  • 38.

    Gemzar [package insert]. Indianapolis, IN: Eli Lilly & Co; 2004.

  • 39.

    Camptosar [package insert]. New York, NY: Pfizer Inc; 2004.

  • 40.

    Hycamtin [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2003.

  • 41.

    Xeloda [package insert]. Nutley, NJ: Roche Pharmaceuticals; 2003.

  • 42.

    Ellence [package insert]. Kalamazoo, MI: Pharmacia & Upjohn; 2003.

  • 43.

    Eloxatin [package insert]. New York, NY: Sanofi-Synthelabo; 2004.

  • 44.

    Arriagada R, Bergman B, Dunant A. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351360.

    • Search Google Scholar
    • Export Citation
  • 45.

    Strauss GM, Herndon J, Maddaus MA. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) protocol 9633 [Abstract]. Presented at the 40th Annual Meeting of the American Society of Clinical Oncology; June 5–8, 2004; New Orleans, LA. Abstract #7019.

    • Search Google Scholar
    • Export Citation
  • 46.

    Winton TL, Livingston R, Johnson D. Vinorelbine plus cisplatin vs. observation in resected non small cell lung cancer. N Engl J Med 2005;352:25892597.

    • Search Google Scholar
    • Export Citation
  • 47.

    Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998;352:930942.

    • Search Google Scholar
    • Export Citation
  • 48.

    Mackey JR, Paterson A, Dirix LY. Final results of the phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FAC as first line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC) [Abstract]. Proc Am Soc Clin Oncol 2002;21:35a. Abstract #137.

    • Search Google Scholar
    • Export Citation
  • 49.

    Martin M, Pienkowski T, Mackay J. TAC improves disease free survival and overall survival over FAC in node positive early breast cancer patients, BCIRG 001: 55 months follow-up [abstract 43]. Presented at the 26th Annual San Antonio Breast Cancer Symposium; December 3–6, 2003; San Antonio, TX. Abstract #43.

    • Search Google Scholar
    • Export Citation
  • 50.

    Citron ML, Berry DA, Cirrincione C. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup trial C9741/Cancer and Leukemia Group B trial 9741. J Clin Oncol 2003;21:14311439. [erratum in J Clin Oncol 2003;21: 2226].

    • Search Google Scholar
    • Export Citation
  • 51.

    Andre T, Boni C, Mounedji-Boudiaf L. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:23432351.

    • Search Google Scholar
    • Export Citation
  • 52.

    Mamounas E, Wieand S, Wolmark N. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 1999;17:13491355.

    • Search Google Scholar
    • Export Citation
  • 53.

    International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol 1999;17:13561363.

    • Search Google Scholar
    • Export Citation
  • 54.

    Gill S, Loprinzi CL, Sargent DJ. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 2004;22:17971806.

    • Search Google Scholar
    • Export Citation
  • 55.

    Gray RG, Barnwell J, Hills R. QUASAR: a randomized study of adjuvant chemotherapy (CT) vs observation including 3238 colorectal cancer patients [Abstract]. Proc Am Soc Clin Oncol 2004;23:246. Abstract #3501.

    • Search Google Scholar
    • Export Citation
  • 56.

    Cullen MH, Billingham LJ, Woodroffe CM. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 1999;17:31883194.

    • Search Google Scholar
    • Export Citation
  • 57.

    Marino P, Pampallona S, Preatoni A. Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature. Chest 1994;106:861865.

    • Search Google Scholar
    • Export Citation
  • 58.

    Grilli R, Oxman AD, Julian JA. Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? J Clin Oncol 1993;11:18661872.

    • Search Google Scholar
    • Export Citation
  • 59.

    Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311:899909.

    • Search Google Scholar
    • Export Citation
  • 60.

    Bonomi PD, Finkelstein DM, Ruckdeschel JC. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol 1989;7:16021613.

    • Search Google Scholar
    • Export Citation
  • 61.

    Gandara DR, Crowley J, Livingston RB. Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group. J Clin Oncol 1993;11:873878.

    • Search Google Scholar
    • Export Citation
  • 62.

    Klastersky J, Sculier JP, Bureau G. Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small-cell lung cancer. Lung Cancer Working Party, Belgium. J Clin Oncol 1989;7:10871092.

    • Search Google Scholar
    • Export Citation
  • 63.

    Rapp E, Pater JL, Willan A. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer—report of a Canadian multicenter randomized trial. J Clin Oncol 1988;6:633641.

    • Search Google Scholar
    • Export Citation
  • 64.

    Ruckdeschel JC, Finkelstein DM, Ettinger DS. A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. J Clin Oncol 1986;4:1422.

    • Search Google Scholar
    • Export Citation
  • 65.

    Ettinger DS. Is there a preferred combination chemotherapy regimen for metastatic non-small cell lung cancer? Oncologist 2002;7:226233.

    • Search Google Scholar
    • Export Citation
  • 66.

    de Gramont A, Figer A, Seymour M. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:29382947.

    • Search Google Scholar
    • Export Citation
  • 67.

    Crawford J, Ozer H, Stoller R. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325:164170.

    • Search Google Scholar
    • Export Citation
  • 68.

    Trillet-Lenoir V, Green J, Manegold C. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993;29A:319324.

    • Search Google Scholar
    • Export Citation
  • 69.

    Holmes FA, O'Shaughnessy JA, Vukelja S. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002;20:727731.

    • Search Google Scholar
    • Export Citation
  • 70.

    Green MD, Koelbl H, Baselga A. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003;14:2935.

    • Search Google Scholar
    • Export Citation
  • 71.

    Del Mastro L, Venturini M, Lionetto R. Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia. J Clin Oncol 1997;15:27152721.

    • Search Google Scholar
    • Export Citation
  • 72.

    Dunphy FR, Harrison BR, Dunleavy TL. Erythropoietin reduces anemia and transfusions: a randomized trial with or without erythropoietin during chemotherapy. Cancer 1999;86:13621367.

    • Search Google Scholar
    • Export Citation
  • 73.

    Vansteenkiste J, Pirker R, Massuti B. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94:12111220.

    • Search Google Scholar
    • Export Citation
  • 74.

    Crawford J, Wolff DA, Culakova E. First cycle risk of severe and febrile neutropenia in cancer patients receiving systemic chemotherapy: results from a prospective nationwide study [Abstract]. Blood 2004;104:607a608a. Abstract #2210.

    • Search Google Scholar
    • Export Citation
  • 75.

    Lyman GH, Morrison VA, Dale DC. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy. Leuk Lymphoma 2003;44:20692076.

    • Search Google Scholar
    • Export Citation
  • 76.

    National Comprehensive Cancer Network. NCCN Senior Adult Clinical Practice Guidelines, version 1, 2005. Available at:.nccn.org/professionals/physician_gls. Accessed June 13, 2006.

    • Search Google Scholar
    • Export Citation
  • 77.

    Martin M, Lluch A, Segui MA. Prophylactic growth factor (GF) support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-negative breast cancer (BC): an interim safety analysis of the GEICAM 9805 study [Abstract]. Proc Am Soc Clin Oncol 2004;23:32. Abstract #620.

    • Search Google Scholar
    • Export Citation
  • 78.

    Ellis GK, Livingston RB, Gralow JR, Green SJ, Thompson T. Dose-dense anthracycline-based chemotherapy for node-positive breast cancer. J Clin Oncol 2002;20:36373643.

    • Search Google Scholar
    • Export Citation
  • 79.

    Burstein HJ, Parker LM, Doherty J. Use of the long-acting hematopoietic growth factors pegfilgrastim and darbepoetin alfa in support of dose-dense adjuvant chemotherapy [Abstract]. Presented at the 27th Annual San Antonio Breast Cancer Symposium; December 8–11, 2004; San Antonio, TX. Abstract #1055.

    • Search Google Scholar
    • Export Citation
  • 80.

    National Comprehensive Cancer Network. NCCN Cancer and Treatment-Related Anemia Clinical Practice Guidelines, version 2, 2006. Available at: http://www.nccn.org/professionals/physician_gls/PDF/anemia.pdf. Accessed May 23, 2006.

    • Search Google Scholar
    • Export Citation
  • 81.

    Garst J. Role of erythropoietin agents in patients with lung cancer. Am Soc Clin Oncol Educ Book 2004:476-479.

  • 82.

    Balducci L. Anemia, cancer, and aging. Cancer Control 2003;10:478486.

  • 83.

    Barrett-Lee PJ, Bailey NP, O'Brien ME, Wager E. Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy. Br J Cancer 2000;82:9397.

    • Search Google Scholar
    • Export Citation
  • 84.

    Skillings JR, Sridhar FG, Wong C, Paddock L. The frequency of red cell transfusion for anemia in patients receiving chemotherapy. A retrospective cohort study. Am J Clin Oncol 1993;16:2225.

    • Search Google Scholar
    • Export Citation
  • 85.

    Wood PA, Hrushesky WJ. Cisplatin-associated anemia: an erythropoietin deficiency syndrome. J Clin Invest 1995;95:16501659.

  • 86.

    Dische S. Radiotherapy and anaemia—the clinical experience. Radiother Oncol 1991;20(suppl 1):3540.

  • 87.

    Obermair A, Petru E, Windbichler G. Significance of pretreatment serum hemoglobin and survival in epithelial ovarian cancer. Oncol Rep 2000;7:639-644.

    • Search Google Scholar
    • Export Citation
  • 88.

    Lee WR, Berkey B, Marcial V. Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG 85-27. Int J Radiat Oncol Biol Phys 1998;42:10691075.

    • Search Google Scholar
    • Export Citation
  • 89.

    Grogan M, Thomas GM, Melamed I. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 1999;86:15281536.

    • Search Google Scholar
    • Export Citation
  • 90.

    Semrau R, Mueller R-P, Stuetzer H. Ceiling effect of haemoglobin (HB)-levels increasing efficacy of intensified hyperfractionated (HF) and accelerated (ACC) radiotherapy (RT) and concurrent chemotherapy with carboplatin and 5-FU—updated results of a randomized multicentric German trial in advanced head and neck cancer [Abstract]. Presented at the 2004 ASTRA Annual Meeting; October 3–7, 2004; Atlanta, GA. Abstract #101.

    • Search Google Scholar
    • Export Citation
  • 91.

    National Cancer Institute. Clinical trials page. Available at: http://www.cancer.gov/clinicaltrials/findtrials. Accessed May 23, 2006.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 229 130 16
PDF Downloads 200 132 9
EPUB Downloads 0 0 0